Table 3.
Controls (n=20) | FD Subgroups | P Valuea | P Valueb | |||
---|---|---|---|---|---|---|
1 (n=20) | 2 (n=20) | 3 (n=20) | ||||
PICP, ng/mL | 107.3 (39.3) | 148.5 (129.0) | 115.7 (88.8) | 219.0 (98.4) | 0.006 | 0.001 |
PICP/B‐AP | 10.1 (4.3) | 16.2 (10.3) | 12.7 (9.1) | 19.4 (24.1) | 0.003 | 0.001 |
ICTP, ng/mL | 0.34 (0.20) | 0.25 (0.27) | 0.20 (0.19) | 0.29 (0.23) | 0.687 | 0.236 |
ICTP/TRAP5b | 0.11 (0.07) | 0.16 (0.10) | 0.11 (0.07) | 0.13 (0.06) | 0.011 | 0.186 |
MMP1, ng/mL | 16.8 (26.3) | 13.5 (19.3) | 14.1 (4.3) | 9.6 (4.6) | 0.159 | 0.002 |
MMP2, ng/mL | 440.3 (541.0) | 341.8 (849.5) | 356.5 (187.0) | 318.7 (101.9) | 0.872 | 0.108 |
Data are shown as median (interquartile range). B‐AP indicates bone‐specific alkaline phosphatase; FD, Fabry disease; ICTP, carboxyterminal telopeptide of type I collagen; MMP, matrix metalloproteinase; PICP, carboxyterminal propeptide of procollagen type I; TRAP5b, tartrate‐resistant acid phosphatase type 5b.
Controls vs FD disease subgroup 1.
Between FD subgroups.